UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer

Current treatment options in oncology, 2024-09, Vol.25 (9), p.1225-1237

2024

Volltextzugriff (PDF)

Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer

Current treatment options in oncology, 2024-09, Vol.25 (9), p.1210-1224

2024

Volltextzugriff (PDF)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Breast cancer research : BCR, 2019-11, Vol.21 (1), p.121-121, Article 121

2019

Volltextzugriff (PDF)

Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype

Radiology, 2015-11, Vol.277 (2), p.358-371

2015

Volltextzugriff (PDF)

Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer

European radiology, 2013-09, Vol.23 (9), p.2420-2431

2013

Volltextzugriff (PDF)

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer

JNCI : Journal of the National Cancer Institute, 2012-12, Vol.104 (24), p.1879-1887

2012

Volltextzugriff (PDF)

Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?

Journal of the National Comprehensive Cancer Network, 2021-08, Vol.19 (8), p.xxx

2021

Volltextzugriff (PDF)

Nonpalpable breast lesions: impact of a second-opinion review at a breast unit on BI-RADS classification

European radiology, 2021-08, Vol.31 (8), p.5913-5923

2021

Volltextzugriff (PDF)

NF-kappa B genes have a major role in inflammatory breast cancer

BMC cancer, 2008-02, Vol.8 (1), p.41-41, Article 41

2008

Volltextzugriff (PDF)

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial

Journal of clinical oncology, 2019-03, Vol.37 (8), p.624-635

2019

Volltextzugriff (PDF)

p53 in breast cancer subtypes and new insights into response to chemotherapy

Breast (Edinburgh), 2013-08, Vol.22, p.S27-S29

2013

Volltextzugriff (PDF)

The sentinel node procedure in breast cancer: nuclear medicine as the starting point

Journal of Nuclear Medicine, 2011-03, Vol.52 (3), p.405-414

2011

Volltextzugriff (PDF)

Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumors

Cancer, 2013-06, Vol.119 (11), p.1960-1968

2013

Volltextzugriff (PDF)

Performance of FDG PET/CT in the clinical management of breast cancer

Radiology, 2013-02, Vol.266 (2), p.388-405

2013

Volltextzugriff (PDF)

Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symptoms, inhibit the CYP2D6 enzyme system?

Menopause (New York, N.Y.), 2015-11, Vol.22 (11), p.1212-1214

2015

Volltextzugriff (PDF)

Intraoperative Radiotherapy for Breast Cancer in Elderly Women

Clinical breast cancer, 2022-01, Vol.22 (1), p.e109-e113

2022

Volltextzugriff (PDF)

10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment

Radiotherapy and oncology, 2017-01, Vol.122 (1), p.11-16

2017

Volltextzugriff (PDF)

Prospective analysis of the impact of VEGF‐A gene polymorphisms on the pharmacodynamics of bevacizumab‐based therapy in metastatic breast cancer patients

British journal of clinical pharmacology, 2011-06, Vol.71 (6), p.921-928

2011

Volltextzugriff (PDF)

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

Breast cancer research : BCR, 2017-01, Vol.19 (1), p.3-3, Article 3

2017

Volltextzugriff (PDF)

Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis

Anticancer research, 2015-03, Vol.35 (3), p.1729-1734

2015

Volltextzugriff (PDF)

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1008-1008

2018

Volltextzugriff (PDF)

1 – 25 von 206

Suche als RSS-Feed

Aktive Filter

ThemaCancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(163)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(101)
Female
(90)
Science & Technology
(82)
Life Sciences & Biomedicine
(81)
Oncology
(62)
Breast Cancer
(58)
Middle Aged
(51)
Adult
(50)
Breast Neoplasms - Pathology
(48)
Aged
(41)
Breast Neoplasms - Drug Therapy
(40)
Tumors
(30)
Treatment Outcome
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(25)
Chemotherapy
(24)
Prognosis
(23)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Breast Neoplasms - Mortality
(20)
Breast Neoplasms - Diagnostic Imaging
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer

Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial

Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer

Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?

Nonpalpable breast lesions: impact of a second-opinion review at a breast unit on BI-RADS classification

NF-kappa B genes have a major role in inflammatory breast cancer

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial

p53 in breast cancer subtypes and new insights into response to chemotherapy

The sentinel node procedure in breast cancer: nuclear medicine as the starting point

Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumors

Performance of FDG PET/CT in the clinical management of breast cancer

Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symptoms, inhibit the CYP2D6 enzyme system?

Intraoperative Radiotherapy for Breast Cancer in Elderly Women

10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment

Prospective analysis of the impact of VEGF‐A gene polymorphisms on the pharmacodynamics of bevacizumab‐based therapy in metastatic breast cancer patients

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)

Aktive Filter

Suchergebnisse filtern